Key result
Fimasartan effectively treats hypertension and offers renoprotective benefits in diabetes.
Why the study?
Fimasartan is a new angiotensin receptor blocker with greater potency and longer action, requiring summary of its pharmacology and clinical evidence.
Fimasartan is a potent, long-acting angiotensin receptor blocker with renoprotective effects and benefits in diabetes for the treatment of hypertension.
Fimasartan may offer 24-hour BP control with renoprotection in diabetes; leaves open comparative efficacy versus established ARBs.
Hypertension is a major public health problem of modern era. Fimasartan is a new Angiotensin Receptor Blocker approved for treatment of hypertension. It is more potent and longer acting angiotensin receptor blocker with effects lasting over 24 hours. Many clinical studies have affirmed its role in pharmacotherapy of hypertension. Further, it is renoprotective and has proven beneficial in diabetes also. This article briefly discusses the pharmacology and clinical evidence with fimasartan with a short summary of previous angiotensin receptor blockers.
No takes yet. Share an insight, caveat, or question.
Pradhan et al. (2019) conducted a review in Hypertension. Fimasartan was evaluated. Fimasartan is a potent, long-acting angiotensin receptor blocker that is effective for hypertension and offers renoprotective benefits in diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: